Hospital-acquired acute kidney injury (HA-AKI) is a common and serious clinical syndrome defined as AKI developing after hospital admission, typically diagnosed using KDIGO serum creatinine and urine output criteria. It represents a convergent endpoint arising from overlapping inpatient insults including sepsis, nephrotoxic drug exposure, perioperative hemodynamic instability, and contrast media administration. HA-AKI affects 10-25% of hospitalized patients overall and up to 50-60% of ICU patients, with in-hospital mortality rates of 30-45% for ICU-acquired cases. Despite advances in recognition and supportive care, effective preventive and therapeutic strategies remain limited, and HA-AKI is an independent risk factor for progression to chronic kidney disease.
Ask a research question about Hospital-Acquired Acute Kidney Injury. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Hospital-Acquired Acute Kidney Injury
creation_date: "2026-03-09T12:00:00Z"
updated_date: "2026-04-14T20:40:00Z"
category: Complex
parents:
- Renal Disease
disease_term:
preferred_term: hospital-acquired acute kidney injury
term:
id: MONDO:0002492
label: acute kidney injury
description: >
Hospital-acquired acute kidney injury (HA-AKI) is a common and serious
clinical syndrome defined as AKI developing after hospital admission,
typically diagnosed using KDIGO serum creatinine and urine output criteria.
It represents a convergent endpoint arising from overlapping inpatient insults
including sepsis, nephrotoxic drug exposure, perioperative hemodynamic
instability, and contrast media administration. HA-AKI affects 10-25% of
hospitalized patients overall and up to 50-60% of ICU patients, with
in-hospital mortality rates of 30-45% for ICU-acquired cases. Despite
advances in recognition and supportive care, effective preventive and
therapeutic strategies remain limited, and HA-AKI is an independent risk
factor for progression to chronic kidney disease.
has_subtypes:
- name: Sepsis-Associated AKI
description: >
AKI developing as a complication of sepsis in hospitalized patients,
driven by systemic inflammation, microvascular dysfunction, and tubular cell injury.
- name: Nephrotoxic AKI
description: >
AKI caused by exposure to nephrotoxic agents including aminoglycosides,
contrast media, NSAIDs, and vancomycin during hospitalization.
- name: Postoperative AKI
description: >
AKI developing after major surgery, particularly cardiac, vascular, or
abdominal procedures, due to perioperative hemodynamic instability and ischemia.
- name: Contrast-Induced AKI
description: >
AKI following intra-arterial or intravenous administration of iodinated
contrast media for diagnostic or interventional procedures.
pathophysiology:
- name: Ischemic Tubular Injury
description: >
Renal hypoperfusion from sepsis, major surgery, or hemodynamic instability
causes ischemia-reperfusion injury to tubular epithelial cells, leading to
acute tubular necrosis (ATN), the most common cause of hospital-acquired AKI.
Tubular cell death occurs through regulated necrosis pathways including
necroptosis and ferroptosis, with subsequent release of cytosolic components
that amplify inflammation.
locations:
- preferred_term: Proximal Tubule
term:
id: UBERON:0004134
label: proximal tubule
- preferred_term: Renal Tubule
term:
id: UBERON:0009773
label: renal tubule
cell_types:
- preferred_term: Proximal Tubular Epithelial Cell
term:
id: CL:0002306
label: epithelial cell of proximal tubule
- preferred_term: Peritubular Capillary Endothelial Cell
term:
id: CL:1001033
label: peritubular capillary endothelial cell
biological_processes:
- preferred_term: Ischemic Response
term:
id: GO:0002931
label: response to ischemia
- preferred_term: Programmed Necrotic Cell Death
term:
id: GO:0097300
label: programmed necrotic cell death
- preferred_term: Apoptotic Process
term:
id: GO:0006915
label: apoptotic process
evidence:
- reference: PMID:31005270
reference_title: "Regulated necrosis in kidney ischemia-reperfusion injury."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Tubular cell death by necrosis and apoptosis is a central feature of renal IRI. Recent research has challenged traditional views of cell death by identifying new pathways in which cells die in a regulated manner but with the morphologic features of necrosis."
explanation: Demonstrates that regulated necrosis (necroptosis and ferroptosis) alongside apoptosis are central mechanisms of tubular injury in renal ischemia-reperfusion.
- reference: PMID:25057935
reference_title: "Postoperative acute kidney injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Acute kidney injury (AKI) represents 18-47% of all causes of hospital-acquired AKI and it is associated with a high incidence of morbidity and mortality especially in patients requiring dialysis."
explanation: Postoperative AKI is a major contributor to hospital-acquired AKI, confirming ischemic tubular injury as a predominant mechanism.
- name: Nephrotoxic Injury
description: >
Exposure to nephrotoxic agents such as aminoglycosides, contrast media,
NSAIDs, and vancomycin causes direct tubular cell damage and apoptosis,
contributing to a significant proportion of hospital-acquired AKI cases.
Contrast-induced AKI is the third leading cause of hospital-acquired AKI.
locations:
- preferred_term: Proximal Tubule
term:
id: UBERON:0004134
label: proximal tubule
cell_types:
- preferred_term: Proximal Tubular Epithelial Cell
term:
id: CL:0002306
label: epithelial cell of proximal tubule
biological_processes:
- preferred_term: Apoptotic Process
term:
id: GO:0006915
label: apoptotic process
- preferred_term: Response to Oxidative Stress
term:
id: GO:0006979
label: response to oxidative stress
evidence:
- reference: PMID:29802583
reference_title: "Contrast medium induced acute kidney injury: a narrative review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Contrast-induced acute kidney injury (CI-AKI) is the third leading cause of hospital-acquired acute kidney injury."
explanation: Confirms that contrast media nephrotoxicity is a major contributor to hospital-acquired AKI.
- reference: PMID:34537763
reference_title: "Hospital-Acquired Acute Kidney Injury in Older Patients: Clinical Characteristics and Drug Analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In the HA-AKI group, the proportion of patients with prior use of drugs with possible nephrotoxicity was higher than that of patients with prior use of drugs with identified nephrotoxicity (p < 0.05)."
explanation: Demonstrates that nephrotoxic drug exposure is a key risk factor for hospital-acquired AKI in older patients.
- name: Sepsis-Associated AKI
description: >
Systemic inflammation during sepsis triggers a complex interplay of
microvascular dysfunction, inflammatory mediator release, and tubular
cell injury through both ischemic and non-ischemic pathways. Recent evidence
shows renal blood flow may be normal or increased in early sepsis-AKI,
suggesting microvascular and inflammatory mechanisms predominate over
global hypoperfusion.
locations:
- preferred_term: Renal Glomerulus
term:
id: UBERON:0000074
label: renal glomerulus
- preferred_term: Kidney Vasculature
term:
id: UBERON:0006544
label: kidney vasculature
cell_types:
- preferred_term: Glomerular Endothelial Cell
term:
id: CL:0002188
label: glomerular endothelial cell
- preferred_term: Kidney Resident Macrophage
term:
id: CL:1000698
label: kidney resident macrophage
- preferred_term: Proximal Tubular Epithelial Cell
term:
id: CL:0002306
label: epithelial cell of proximal tubule
biological_processes:
- preferred_term: Inflammatory Response
term:
id: GO:0006954
label: inflammatory response
- preferred_term: Cell Death
term:
id: GO:0008219
label: cell death
evidence:
- reference: PMID:29273917
reference_title: "Recent advances in the pathogenetic mechanisms of sepsis-associated acute kidney injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "increasing importance is now attributed to kidney damage resulting from a complex interaction between immunologic mechanisms, inflammatory cascade activation, and deranged coagulation pathways, leading to microvascular dysfunction, endothelial damage, leukocyte/platelet activation with the formation of micro-thrombi, epithelial tubular cell injury and dysfunction."
explanation: Describes the multifactorial pathogenesis of sepsis-associated AKI involving inflammation, coagulation, microvascular dysfunction, and tubular injury.
- reference: PMID:33494815
reference_title: "Sepsis is associated with mitochondrial DNA damage and a reduced mitochondrial mass in the kidney of patients with sepsis-AKI."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Up to 60% of patients with sepsis develop acute kidney injury (AKI), which is associated with a poor clinical outcome."
explanation: Documents the high incidence of AKI in sepsis patients and its association with poor outcomes, supporting sepsis as a major driver of hospital-acquired AKI.
- reference: PMID:25845505
reference_title: "Acute kidney injury in severe sepsis: pathophysiology, diagnosis, and treatment recommendations."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Sepsis-induced AKI is diagnosed in up to 47% of human ICU patients and is seen as a major public health concern associated with increased mortality and increased progression to chronic kidney disease (CKD)."
explanation: Review published in a veterinary journal synthesizing human data on sepsis-induced AKI prevalence in ICU patients.
- name: Mitochondrial Dysfunction
description: >
Mitochondrial damage and reduced mitochondrial mass in renal tubular
epithelial cells contribute to the pathogenesis of AKI, particularly in
sepsis-associated cases. Oxidative DNA damage and impaired mitochondrial
quality control pathways exacerbate tubular injury.
cell_types:
- preferred_term: Proximal Tubular Epithelial Cell
term:
id: CL:0002306
label: epithelial cell of proximal tubule
biological_processes:
- preferred_term: Response to Oxidative Stress
term:
id: GO:0006979
label: response to oxidative stress
evidence:
- reference: PMID:33494815
reference_title: "Sepsis is associated with mitochondrial DNA damage and a reduced mitochondrial mass in the kidney of patients with sepsis-AKI."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Compared to control subjects, sepsis-AKI patients had upregulated mRNA expression of oxidative damage markers, excess mitochondrial DNA damage and lower mitochondrial mass."
explanation: Demonstrates that mitochondrial DNA damage and reduced mitochondrial mass are present in the kidneys of sepsis-AKI patients.
- reference: PMID:26924060
reference_title: "Autophagy in acute kidney injury."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Damaged mitochondria accumulate in autophagy-deficient kidneys of mice subjected to ischemia-reperfusion injury, but the precise mechanisms of regulation of mitophagy in AKI are not yet elucidated."
explanation: Demonstrates that impaired mitophagy leads to accumulation of damaged mitochondria in AKI, supporting mitochondrial dysfunction as a key pathogenic mechanism.
phenotypes:
- category: Genitourinary
name: Oliguria
description: Reduced urine output below 0.5 mL/kg/hr, a hallmark clinical feature of AKI used in KDIGO staging criteria.
phenotype_term:
preferred_term: Oliguria
term:
id: HP:0100520
label: Oliguria
evidence:
- reference: PMID:35685550
reference_title: "Hospital-Acquired Acute Kidney Injury in Noncritical Care Setting: Clinical Characteristics and Outcomes."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "HA-AKI was defined using the Kidney Disease Improving Global Outcomes (KDIGO) criteria."
explanation: KDIGO criteria for AKI staging include oliguria as a key diagnostic feature alongside serum creatinine elevation.
- category: Genitourinary
name: Elevated Serum Creatinine
description: >
Rise in serum creatinine of ≥0.3 mg/dL within 48 hours or ≥1.5 times
baseline within 7 days, per KDIGO criteria. The defining biochemical
hallmark of AKI.
phenotype_term:
preferred_term: Elevated Serum Creatinine
term:
id: HP:0003259
label: Elevated circulating creatinine concentration
evidence:
- reference: PMID:26231194
reference_title: "Epidemiology and Clinical Correlates of AKI in Chinese Hospitalized Adults."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "AKI was defined and staged according to Kidney Disease Improving Global Outcomes criteria."
explanation: AKI diagnosis relies on serum creatinine elevation according to standardized KDIGO criteria.
- category: Metabolism
name: Metabolic Acidosis
description: >
Impaired renal acid excretion leads to accumulation of metabolic acids
and decreased serum bicarbonate.
phenotype_term:
preferred_term: Metabolic Acidosis
term:
id: HP:0001942
label: Metabolic acidosis
evidence:
- reference: PMID:32397637
reference_title: "Timing of Initiation of Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Established and widely accepted indications for starting RRT include refractory fluid overload, severe hyperkalemia and metabolic acidosis refractory to medical therapy"
explanation: Metabolic acidosis is a recognized complication of severe AKI requiring renal replacement therapy.
- category: Metabolism
name: Hyperkalemia
description: >
Elevated serum potassium due to decreased renal excretion, posing risk
of cardiac arrhythmias and a key indication for renal replacement therapy.
phenotype_term:
preferred_term: Hyperkalemia
term:
id: HP:0002153
label: Hyperkalemia
evidence:
- reference: PMID:32397637
reference_title: "Timing of Initiation of Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Established and widely accepted indications for starting RRT include refractory fluid overload, severe hyperkalemia and metabolic acidosis refractory to medical therapy"
explanation: Hyperkalemia is a life-threatening complication of AKI and one of the established indications for initiating RRT.
- category: Genitourinary
name: Fluid Overload
description: >
Inability to excrete excess fluid leads to peripheral edema, pulmonary
edema, and hypertension. A common complication of AKI that may require
renal replacement therapy.
phenotype_term:
preferred_term: Edema
term:
id: HP:0000969
label: Edema
evidence:
- reference: PMID:32397637
reference_title: "Timing of Initiation of Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Established and widely accepted indications for starting RRT include refractory fluid overload, severe hyperkalemia and metabolic acidosis refractory to medical therapy"
explanation: Refractory fluid overload is a recognized complication of AKI and an indication for initiating renal replacement therapy.
- category: Genitourinary
name: Azotemia
description: >
Accumulation of nitrogenous waste products (urea and creatinine) in the
blood due to impaired renal clearance.
phenotype_term:
preferred_term: Azotemia
term:
id: HP:0002157
label: Azotemia
evidence:
- reference: PMID:32397637
reference_title: "Timing of Initiation of Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Acute complications related to AKI are diverse and depend on the severity of the insult."
explanation: Azotemia (accumulation of nitrogenous wastes) is a core feature of AKI driving uremic complications.
- category: Genitourinary
name: Proteinuria
description: >
Presence of excess protein in urine due to tubular damage or glomerular
dysfunction in AKI.
phenotype_term:
preferred_term: Proteinuria
term:
id: HP:0000093
label: Proteinuria
evidence:
- reference: PMID:28927644
reference_title: "Acute kidney injury is a risk factor for subsequent proteinuria."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "AKI is a risk factor for incident or worsening proteinuria, suggesting a possible mechanism linking AKI and future CKD."
explanation: Large Veterans cohort study demonstrates that AKI causes new-onset or worsening proteinuria, with odds ratios of 1.20-1.39 across months of follow-up, and higher odds with more severe AKI stages.
environmental:
- name: Nephrotoxic Drug Exposure
description: >
Exposure to nephrotoxic medications during hospitalization including
aminoglycosides, vancomycin, NSAIDs, and ACE inhibitors is a major
modifiable risk factor for hospital-acquired AKI.
environment_context:
preferred_term: healthcare facility
term:
id: ENVO:03501134
label: healthcare facility
evidence:
- reference: PMID:34537763
reference_title: "Hospital-Acquired Acute Kidney Injury in Older Patients: Clinical Characteristics and Drug Analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Nephrotoxic drug exposure and HA-AKI incidence were associated with an increased in-hospital mortality risk."
explanation: Nephrotoxic drug exposure is independently associated with both HA-AKI incidence and mortality.
- reference: PMID:26231194
reference_title: "Epidemiology and Clinical Correlates of AKI in Chinese Hospitalized Adults."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "About 40% of AKI cases were possibly drug-related and 16% may have been induced by Chinese traditional medicines or remedies."
explanation: Drug-related causes account for a large proportion of hospital-acquired AKI cases.
- name: Contrast Media Exposure
description: >
Intra-arterial or intravenous administration of iodinated contrast media
for diagnostic or interventional procedures is a well-established cause
of hospital-acquired AKI.
environment_context:
preferred_term: healthcare facility
term:
id: ENVO:03501134
label: healthcare facility
evidence:
- reference: PMID:29802583
reference_title: "Contrast medium induced acute kidney injury: a narrative review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Pre-existing CKD, intra-arterial administration and CM volume are the most important risk factors for CI-AKI."
explanation: Identifies key risk factors for contrast-induced AKI, establishing contrast media as a significant cause of hospital-acquired AKI.
- name: Sepsis
description: >
Sepsis is the leading cause of AKI in critically ill hospitalized patients,
with up to 60% of sepsis patients developing AKI.
environment_context:
preferred_term: intensive care unit
term:
id: ENVO:03600008
label: intensive care unit
evidence:
- reference: PMID:33494815
reference_title: "Sepsis is associated with mitochondrial DNA damage and a reduced mitochondrial mass in the kidney of patients with sepsis-AKI."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Up to 60% of patients with sepsis develop acute kidney injury (AKI), which is associated with a poor clinical outcome."
explanation: Establishes sepsis as a major environmental trigger for hospital-acquired AKI in critically ill patients.
- name: Major Surgery
description: >
Major surgical procedures, particularly cardiac and vascular surgery,
are associated with perioperative hemodynamic instability and
ischemia-reperfusion injury leading to AKI.
environment_context:
preferred_term: healthcare facility
term:
id: ENVO:03501134
label: healthcare facility
evidence:
- reference: PMID:25057935
reference_title: "Postoperative acute kidney injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Multi-hit mechanisms (ischemia, inflammation, toxins) co-act on patients' predisposition (susceptibility)."
explanation: Describes the multi-hit model of postoperative AKI involving ischemia, inflammation, and nephrotoxins.
treatments:
- name: Fluid Resuscitation
description: >
Intravenous fluid administration to restore renal perfusion in
prerenal or ischemic AKI. Isotonic saline or balanced crystalloid
solutions are the mainstay of volume expansion.
treatment_term:
preferred_term: fluid replacement therapy
term:
id: MAXO:0000618
label: fluid replacement therapy
evidence:
- reference: PMID:29802583
reference_title: "Contrast medium induced acute kidney injury: a narrative review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The intravenous administration of moderate amounts of isotonic saline solution or bicarbonate solution still represents the principal intervention with documented and acceptable effectiveness for CI-AKI prevention."
explanation: Volume expansion with isotonic fluids is the most established preventive and therapeutic measure for AKI.
- name: Nephrotoxin Avoidance
description: >
Identification and discontinuation of nephrotoxic medications to
prevent further tubular injury. Includes medication review using
electronic alert systems and AKI care bundles.
treatment_term:
preferred_term: nephrotoxin avoidance
term:
id: MAXO:0000071
label: chemical exposure avoidance
evidence:
- reference: PMID:29188454
reference_title: "A narrative review of the impact of interventions in acute kidney injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "This review found that e-alerts have varying effects on mortality and AKI progression, but decrease the incidence of contrast-induced AKI. The use of AKI bundles delivers statistically significant improvements in mortality and AKI progression."
explanation: Electronic alerts and AKI bundles that include nephrotoxin avoidance improve outcomes in hospital-acquired AKI.
- reference: PMID:34537763
reference_title: "Hospital-Acquired Acute Kidney Injury in Older Patients: Clinical Characteristics and Drug Analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "With the increase in the number of patients with continued use of drugs with possible nephrotoxicity after HA-AKI, the clinical outcomes showed a tendency to worsen (p < 0.001)."
explanation: Continued nephrotoxic drug exposure after AKI onset worsens outcomes, supporting nephrotoxin avoidance as a key intervention.
- name: Renal Replacement Therapy
description: >
Initiation of dialysis (intermittent hemodialysis or continuous renal
replacement therapy) for severe AKI with refractory fluid overload,
hyperkalemia, or uremia. The optimal timing of RRT initiation remains
an area of active investigation.
treatment_term:
preferred_term: renal replacement therapy
term:
id: MAXO:0000600
label: renal replacement therapy
evidence:
- reference: PMID:32397637
reference_title: "Timing of Initiation of Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "No specific treatment has been defined yet, and renal replacement therapy (RRT) remains the cornerstone supportive therapy for the most severe cases."
explanation: RRT is the primary supportive therapy for severe sepsis-associated AKI, though optimal timing of initiation remains debated.
- name: AKI Care Bundles
description: >
Standardized care bundles including fluid optimization, medication review,
monitoring, and nephrology referral to improve early detection and management
of hospital-acquired AKI.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
evidence:
- reference: PMID:29188454
reference_title: "A narrative review of the impact of interventions in acute kidney injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Overall, a combination of e-alerts and AKI bundles supported by education yielded the most effective and statistically significant results."
explanation: Multicomponent AKI care bundles combining electronic alerts, standardized protocols, and education provide the most effective improvements in AKI outcomes.
prevalence:
- population: Hospitalized adults (general)
percentage: 10-25%
evidence:
- reference: PMID:20877177
reference_title: "Hospital-acquired acute kidney injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Acute kidney injury (AKI) is a common clinical syndrome in hospitalized patients associated with high morbidity and mortality rates."
explanation: Establishes AKI as a common syndrome among hospitalized patients, consistent with reported incidence estimates of 10-25%.
- population: ICU patients
percentage: 16-59%
evidence:
- reference: PMID:25845505
reference_title: "Acute kidney injury in severe sepsis: pathophysiology, diagnosis, and treatment recommendations."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Sepsis-induced AKI is diagnosed in up to 47% of human ICU patients and is seen as a major public health concern associated with increased mortality and increased progression to chronic kidney disease (CKD)."
explanation: Veterinary journal review citing human ICU data; up to 47% of ICU patients develop sepsis-associated AKI.
- population: Elderly hospitalized patients
percentage: 15-30%
notes: Higher incidence in older adults due to reduced renal reserve, comorbidities, and polypharmacy
evidence:
- reference: PMID:34537763
reference_title: "Hospital-Acquired Acute Kidney Injury in Older Patients: Clinical Characteristics and Drug Analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In the HA-AKI group, the proportion of patients with prior use of drugs with possible nephrotoxicity was higher than that of patients with prior use of drugs with identified nephrotoxicity (p < 0.05)."
explanation: Elderly patients are disproportionately affected by nephrotoxic drug-related HA-AKI due to polypharmacy and reduced renal reserve.
epidemiology:
- name: ICU HA-AKI incidence
description: Incidence of hospital-acquired AKI among critically ill patients admitted to ICU without AKI on admission.
minimum_value: 16
maximum_value: 59
notes: ICU prospective cohort data report 16.1% HA-AKI incidence with hospital mortality of 43.2% in affected patients.
evidence:
- reference: PMID:25845505
reference_title: "Acute kidney injury in severe sepsis: pathophysiology, diagnosis, and treatment recommendations."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Sepsis-induced AKI is diagnosed in up to 47% of human ICU patients and is seen as a major public health concern associated with increased mortality and increased progression to chronic kidney disease (CKD)."
explanation: Veterinary journal review citing human ICU data on high AKI incidence in sepsis.
- name: ICU HA-AKI mortality
description: In-hospital mortality in patients who develop AKI during ICU stay.
minimum_value: 30
maximum_value: 45
notes: Mortality rates for ICU-acquired AKI are substantially higher than for patients without AKI (14% vs 43%).
evidence:
- reference: PMID:20877177
reference_title: "Hospital-acquired acute kidney injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Acute kidney injury (AKI) is a common clinical syndrome in hospitalized patients associated with high morbidity and mortality rates."
explanation: Confirms AKI is associated with high mortality rates in hospitalized patients.
- name: Under-recognition rate
description: Proportion of AKI episodes not formally diagnosed or coded during hospitalization.
minimum_value: 55
maximum_value: 70
notes: Studies report that 57-66% of creatinine-defined AKI episodes lack administrative documentation, contributing to delayed intervention.
evidence:
- reference: PMID:24075024
reference_title: "The impact of documentation of severe acute kidney injury on mortality."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Formal documentation of AKI occurred in 2,325 patients (43%)."
explanation: In a cohort of 5,438 adults with creatinine-defined AKI across three hospitals, only 43% had formal documentation, meaning 57% of AKI episodes were unrecognized in billing codes.
stages:
- name: KDIGO Stage 1
description: >
Mild AKI defined by serum creatinine increase of ≥0.3 mg/dL (26.5 µmol/L)
within 48 hours OR increase to ≥1.5-1.9 times baseline within 7 days OR
urine output <0.5 mL/kg/h for 6-12 hours.
evidence:
- reference: PMID:23499048
reference_title: "KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The first portion of the KDIGO guideline attempts to harmonize earlier consensus definitions and staging criteria for AKI."
explanation: The KDIGO staging system represents harmonized consensus criteria for defining and staging AKI severity, with Stage 1 as the mildest category.
- reference: PMID:35685550
reference_title: "Hospital-Acquired Acute Kidney Injury in Noncritical Care Setting: Clinical Characteristics and Outcomes."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "HA-AKI was defined using the Kidney Disease Improving Global Outcomes (KDIGO) criteria."
explanation: KDIGO criteria are the standard used to define and stage hospital-acquired AKI in clinical studies.
- name: KDIGO Stage 2
description: >
Moderate AKI defined by serum creatinine increase to 2.0-2.9 times baseline
OR urine output <0.5 mL/kg/h for ≥12 hours.
evidence:
- reference: PMID:23499048
reference_title: "KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "While the expert panel thought that the KDIGO definition and staging criteria are appropriate for defining the epidemiology of AKI and in the design of clinical trials, the panel concluded that there is insufficient evidence to support their widespread application to clinical care in the United States."
explanation: KDIGO Stage 2 criteria are endorsed for epidemiological and clinical trial use, though the panel noted limitations for direct clinical application.
- name: KDIGO Stage 3
description: >
Severe AKI defined by serum creatinine increase to ≥3.0 times baseline
OR increase to ≥4.0 mg/dL (353.6 µmol/L) OR initiation of renal replacement
therapy OR urine output <0.3 mL/kg/h for ≥24 hours OR anuria for ≥12 hours.
In patients <18 years, decrease in eGFR to <35 mL/min/1.73 m².
evidence:
- reference: PMID:23499048
reference_title: "KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The panel generally concurred with the remainder of the KDIGO guidelines that are focused on the prevention and pharmacologic and dialytic management of AKI, although noting the dearth of clinical trial evidence to provide strong evidence-based recommendations and the continued absence of effective therapies beyond hemodynamic optimization and avoidance of nephrotoxins for the prevention and treatment of AKI."
explanation: KDIGO Stage 3 represents the most severe category of AKI, often requiring renal replacement therapy, with limited evidence-based treatment options beyond supportive care.
- reference: PMID:32397637
reference_title: "Timing of Initiation of Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "No specific treatment has been defined yet, and renal replacement therapy (RRT) remains the cornerstone supportive therapy for the most severe cases."
explanation: Stage 3 AKI frequently requires initiation of RRT, which is one of the defining criteria for this stage.
diagnosis:
- name: Serum Creatinine Monitoring
description: Serial measurement of serum creatinine to detect acute rises per KDIGO criteria (≥0.3 mg/dL within 48h or ≥1.5x baseline within 7 days).
evidence:
- reference: PMID:23499048
reference_title: "KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The first portion of the KDIGO guideline attempts to harmonize earlier consensus definitions and staging criteria for AKI."
explanation: Serum creatinine is the primary biochemical parameter used in the KDIGO definition and staging system for AKI.
- reference: PMID:33556265
reference_title: "Current concepts and advances in biomarkers of acute kidney injury."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Despite advancements in standardizing the criteria for acute kidney injury (AKI), its definition remains based on changes in serum creatinine and urinary output that do not specifically represent tubular function or injury and that have significant limitations in the acute hospital setting."
explanation: While creatinine is the standard diagnostic marker, it is a late indicator of injury and has recognized limitations in the acute setting.
- name: Urine Output Monitoring
description: Measurement of hourly urine output to detect oliguria (<0.5 mL/kg/h for 6h) as a KDIGO diagnostic criterion.
evidence:
- reference: PMID:35685550
reference_title: "Hospital-Acquired Acute Kidney Injury in Noncritical Care Setting: Clinical Characteristics and Outcomes."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "HA-AKI was defined using the Kidney Disease Improving Global Outcomes (KDIGO) criteria."
explanation: KDIGO criteria include both creatinine-based and urine-output-based definitions for AKI diagnosis.
- name: Novel Biomarkers (NGAL, KIM-1, TIMP-2, IGFBP7)
description: >
Emerging urinary and plasma biomarkers that detect tubular injury earlier
than serum creatinine. NGAL is released from the distal tubule, KIM-1
from the proximal tubule, and the [TIMP-2]·[IGFBP7] product (NephroCheck)
is FDA-approved for AKI risk assessment.
notes: These biomarkers can localize specific segments of injured tubules and predict AKI-to-CKD transition.
evidence:
- reference: PMID:33556265
reference_title: "Current concepts and advances in biomarkers of acute kidney injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Urinary kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (L-FABP), insulin-like growth factor-binding protein-7 (IGFBP-7), and tissue inhibitor of metalloprotease-2 (TIMP-2) are released from the proximal tubule while uromodulin (UMOD) is secreted from the loop of Henle and neutrophil gelatinase-associated lipocalin (NGAL) is released from the distal tubule."
explanation: Multiple urinary biomarkers can localize tubular injury to specific nephron segments and provide earlier detection than serum creatinine.
- reference: PMID:39298548
reference_title: "Transition from acute kidney injury to chronic kidney disease: mechanisms, models, and biomarkers."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Emerging biomarkers such as kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and soluble tumor necrosis factor receptors (TNFRs) show promise in early detection and monitoring of disease progression."
explanation: KIM-1, NGAL, and TNFRs demonstrate promise for early AKI detection and monitoring progression from AKI to CKD.
progression:
- phase: Acute injury phase (0-7 days)
notes: >
Onset of tubular epithelial cell injury through ischemia, nephrotoxicity,
or sepsis-associated microvascular dysfunction. Characterized by rising
serum creatinine, declining urine output, and activation of regulated
cell death pathways (apoptosis, necroptosis, ferroptosis, pyroptosis).
evidence:
- reference: PMID:31005270
reference_title: "Regulated necrosis in kidney ischemia-reperfusion injury."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Tubular cell death by necrosis and apoptosis is a central feature of renal IRI. Recent research has challenged traditional views of cell death by identifying new pathways in which cells die in a regulated manner but with the morphologic features of necrosis."
explanation: The acute phase is dominated by tubular cell death through both apoptotic and regulated necrosis pathways.
- phase: Acute kidney disease (AKD) window (7-90 days)
notes: >
Period where maladaptive repair mechanisms may drive transition to chronic
disease. Key processes include cell-cycle arrest, persistent inflammation,
mitochondrial dysfunction, metabolic reprogramming, and pericyte-to-myofibroblast
transition. This window represents a critical opportunity for intervention.
evidence:
- reference: PMID:33073587
reference_title: "Mitochondrial dysfunction and the AKI-to-CKD transition."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Recent research has suggested that damage to mitochondrial function in early AKI is a crucial factor leading to tubular injury and persistent renal insufficiency."
explanation: Mitochondrial dysfunction during the AKD window drives persistent tubular injury and incomplete recovery.
- reference: PMID:25810494
reference_title: "Failed Tubule Recovery, AKI-CKD Transition, and Kidney Disease Progression."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "recent studies show that a subpopulation of dedifferentiated, proliferating tubules recovering from AKI undergo pathologic growth arrest, fail to redifferentiate, and become atrophic."
explanation: Failed tubule recovery through pathologic growth arrest and dedifferentiation is a key mechanism during the AKD window that drives progression.
- phase: AKI-to-CKD transition (>90 days)
notes: >
Patients who fail to recover renal function develop progressive fibrosis,
capillary rarefaction, and chronic inflammation leading to CKD. Risk
factors include AKI severity, duration, recurrent episodes, pre-existing
CKD, diabetes, and older age.
evidence:
- reference: PMID:39298548
reference_title: "Transition from acute kidney injury to chronic kidney disease: mechanisms, models, and biomarkers."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "AKI often progresses to CKD due to maladaptive repair processes, persistent inflammation, and fibrosis, with both conditions sharing common pathways involving cell death, inflammation, and extracellular matrix (ECM) deposition."
explanation: AKI and CKD share overlapping pathophysiological mechanisms, with maladaptive repair driving the transition from acute injury to chronic disease.
- reference: PMID:37762322
reference_title: "Pathway from Acute Kidney Injury to Chronic Kidney Disease: Molecules Involved in Renal Fibrosis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Risk factors mentioned in AKI progression to CKD are frequency and severity of kidney injury, chronic diseases such as uncontrolled hypertension, diabetes mellitus, obesity and unmodifiable risk factors (i.e., genetics, older age or gender)."
explanation: Multiple clinical risk factors including AKI severity, comorbidities, and genetic predisposition determine the likelihood of AKI-to-CKD transition.
genetic:
- name: FTO
association: Associated
notes: Locus near FTO on chromosome 16 associated with AKI risk, likely mediated through obesity-related pathways.
evidence:
- reference: PMID:38797326
reference_title: "Genome-wide association study of hospitalized patients and acute kidney injury."
supports: SUPPORT
evidence_source: COMPUTATIONAL
snippet: "Two novel loci reached genome-wide significance in the meta-analysis: rs11642015 near the FTO locus on chromosome 16 (obesity traits) (odds ratio 1.07 (95% confidence interval, 1.05-1.09))"
explanation: GWAS of 54,488 AKI patients identified FTO locus as significantly associated with AKI susceptibility, though the effect was attenuated after adjustment for BMI and diabetes.
- name: SHROOM3
association: Associated
notes: Locus near SHROOM3 on chromosome 4 associated with AKI protection, related to glomerular filtration barrier integrity.
evidence:
- reference: PMID:38797326
reference_title: "Genome-wide association study of hospitalized patients and acute kidney injury."
supports: SUPPORT
evidence_source: COMPUTATIONAL
snippet: "rs4859682 near the SHROOM3 locus on chromosome 4 (glomerular filtration barrier integrity) (odds ratio 0.95 (95% confidence interval, 0.93-0.96))."
explanation: SHROOM3 locus reached genome-wide significance as a protective factor against AKI, with colocalization to previous kidney function studies.
- name: APOE
association: Associated
notes: APO E e2/e3/e4 polymorphism was the only variant with replicated association across multiple early AKI genetic studies.
evidence:
- reference: PMID:19443624
reference_title: "Searching for genes that matter in acute kidney injury: a systematic review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Only one polymorphism, APO E e2/e3/e4, had greater than one study showing a significant impact (P < 0.05) on AKI incidence."
explanation: Systematic review of 16 AKI genetic studies found APOE as the only replicated genetic association across multiple studies.
- name: NR5A2
association: Associated
notes: Variants near NR5A2 gene showed suggestive association with sepsis-associated AKI at sub-genome-wide significance.
evidence:
- reference: PMID:39636799
reference_title: "Genetic variants associated with sepsis-associated acute kidney injury."
supports: PARTIAL
evidence_source: COMPUTATIONAL
snippet: "rs184516290 (chr1:199814965:G:A), near the NR5A2 gene, chr1:199805801:T:TA, also near the NR5A2 gene, and rs117313146 (chr15:31999784:G:C), near the CHRNA7 gene, were associated with S-AKI at the suggestive level in all three models presented."
explanation: NR5A2 variants showed consistent suggestive association with sepsis-AKI but did not reach genome-wide significance threshold.
- name: CHRNA7
association: Associated
notes: Variant near CHRNA7 gene on chromosome 15 showed suggestive association with sepsis-associated AKI across multiple models.
evidence:
- reference: PMID:39636799
reference_title: "Genetic variants associated with sepsis-associated acute kidney injury."
supports: PARTIAL
evidence_source: COMPUTATIONAL
snippet: "rs184516290 (chr1:199814965:G:A), near the NR5A2 gene, chr1:199805801:T:TA, also near the NR5A2 gene, and rs117313146 (chr15:31999784:G:C), near the CHRNA7 gene, were associated with S-AKI at the suggestive level in all three models presented."
explanation: CHRNA7 variant showed consistent suggestive association with sepsis-AKI across three models but did not reach genome-wide significance.
clinical_trials:
- name: NCT02568722
phase: PHASE_III
status: COMPLETED
description: >
STARRT-AKI trial: multinational randomized controlled trial comparing
accelerated versus standard initiation of renal-replacement therapy in
critically ill patients with severe AKI. The accelerated strategy initiated
RRT within 12 hours of eligibility versus a standard strategy where RRT was
discouraged unless conventional indications developed or AKI persisted >72
hours. Found no mortality benefit with accelerated initiation and higher
adverse event rates.
target_phenotypes:
- preferred_term: Acute kidney injury
term:
id: HP:0001919
label: Acute kidney injury
- preferred_term: Oliguria
term:
id: HP:0100520
label: Oliguria
evidence:
- reference: PMID:32668114
reference_title: "Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Among critically ill patients with acute kidney injury, an accelerated renal-replacement strategy was not associated with a lower risk of death at 90 days than a standard strategy."
explanation: This landmark trial of 2927 critically ill AKI patients demonstrated no mortality benefit of accelerated vs standard RRT initiation, with 43.9% vs 43.7% 90-day mortality respectively.
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on the pathophysiology of Hospital-Acquired Acute Kidney Injury. Focus on the molecular and cellular mechanisms underlying disease progression.
Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs
Hospital-acquired AKI is commonly operationalized as AKI that develops after hospital admission, often using an onset cutoff (e.g., >48 h) plus KDIGO creatinine/urine-output criteria; one ICU prospective cohort explicitly defined hospital-acquired AKI as AKI developing after 48 h (KDIGO creatinine-based) (https://doi.org/10.1038/s41598-024-79533-6; published Nov 2024) (havaldar2024epidemiologicalstudyof pages 1-2).
Large-scale hospital surveillance studies also distinguish AKI present at admission vs AKI peaking later during hospitalization, classifying “in-hospital” AKI by the time of peak creatinine after admission (https://doi.org/10.1093/ckj/sfae231; published Jul 2024) (esposito2024recognitionpatternsof pages 7-8).
A major feature of HA-AKI is under-recognition in routine workflows. In a cohort of 56,820 hospitalized adults, serum-creatinine-defined AKI incidence was 24.5%, but most creatinine-defined cases lacked administrative documentation: 16.7% were “KDIGO-AKI” (AKI by creatinine but not coded) versus 3.3% “full-AKI” (meets creatinine criteria and coded), yielding ~68% undetection by discharge coding (https://doi.org/10.1093/ckj/sfae231; Jul 2024) (esposito2024recognitionpatternsof pages 1-2, esposito2024recognitionpatternsof pages 4-6).
This recognition gap matters because undetected AKI still associates with adverse outcomes (esposito2024recognitionpatternsof pages 1-2).
HA-AKI is not a single disease entity; rather, it is a convergent clinical endpoint arising from overlapping insults (hemodynamic perturbations, infection/sepsis, nephrotoxins, hypoxia, surgery). Across settings, mechanistic convergence occurs at the level of:
Renal tubular epithelial cells (TECs)—particularly proximal tubules—are mitochondria-rich and metabolically demanding, and are highlighted as key vulnerable effectors in AKI (https://doi.org/10.1016/j.ebiom.2024.105294; published Sep 2024) (li2024renaltubularepithelial pages 1-2).
Adaptive repair after mild injury involves dedifferentiation, migration, proliferation, and redifferentiation; maladaptive repair links to failed regeneration and fibrosis. A schematic overview of these repair trajectories (resident progenitor vs scattered tubular cell phenotype, adaptive vs maladaptive repair leading to fibrosis) is provided in Figure 1 of Li et al. 2024 (li2024renaltubularepithelial media 407547cb).
A 2024 eBioMedicine review synthesizes TEC death modalities as drivers of tubular damage and subsequent inflammation: - Apoptosis (caspase-mediated, comparatively non-inflammatory) (li2024renaltubularepithelial pages 2-3). - Necroptosis (RIPK-dependent, MLKL-mediated membrane rupture) promoting “necroinflammation,” immune activation, and impaired tubular regeneration (li2024renaltubularepithelial pages 2-3). - Pyroptosis (gasdermin pore formation) releasing DAMPs and inflammatory mediators (li2024renaltubularepithelial pages 2-3). - Ferroptosis (iron-dependent phospholipid peroxidation) emphasized as an important contributor across AKI models, with tubular-segment synchronized injury and protective effects of ferroptosis inhibition (li2024renaltubularepithelial pages 2-3, li2024renaltubularepithelial pages 11-12). - PANoptosis is described as an integrated program enabling simultaneous engagement of pyroptosis, apoptosis, and necroptosis via PANoptosome complexes (li2024renaltubularepithelial pages 1-2).
These death programs directly shape the inflammatory microenvironment of the kidney and influence whether repair is adaptive or fibrogenic (li2024renaltubularepithelial pages 2-3, li2024renaltubularepithelial media 407547cb).
In sepsis-associated contexts (a major HA-AKI driver), a contemporary view is that macro-hemodynamics and total renal blood flow may be preserved, while microcirculatory dysfunction and endothelial activation drive focal hypoxia and injury (https://doi.org/10.7759/cureus.75992; published Dec 2024) (aguilar2024sepsisassociatedacutekidney pages 2-4).
Key inflammatory processes described include cytokine release (e.g., TNF-α, IL-1, IL-6, IL-8), leukocyte adhesion, glycocalyx degradation, microvascular thrombosis, capillary shunting, and oxidative stress/mitochondrial dysfunction (aguilar2024sepsisassociatedacutekidney pages 2-4).
A persistent mechanistic theme in AKI-to-AKD/CKD evolution is mitochondrial dysfunction, metabolic reprogramming, and cell-cycle arrest. A 2023 AKD overview emphasizes tubular epithelial cell-cycle arrest, chronic inflammation, mitochondrial dysfunction, failed regeneration, metabolic reprogramming, and RAS activation as mechanisms linking AKI to later subacute/chronic disease (https://doi.org/10.23876/j.krcp.23.001; published Nov 2023) (kung2023acutekidneydisease pages 1-3).
A TEC-focused synthesis also highlights mitophagy/biogenesis regulators and metabolic nodes (e.g., AMPK, PGC-1α-regulated pathways, and mitochondrial quality control) as important modulators of injury/repair balance (li2024renaltubularepithelial pages 16-16).
Nephrotoxic drugs and combinations are common hospital triggers. - In ICU HA-AKI, colistin exposure was identified as a risk factor in a prospective cohort (havaldar2024epidemiologicalstudyof pages 1-2). - In non-critical medical inpatients, predictors included type 2 diabetes and combined vancomycin + proton pump inhibitors, with mechanistic notes linking vancomycin to proximal tubular oxidative stress and PPIs to immune-mediated AIN-type mechanisms (https://doi.org/10.2147/IJNRD.S454987; published Apr 2024) (mekonnen2024hospitalacquiredacutekidney pages 6-8, mekonnen2024hospitalacquiredacutekidney pages 1-2). - In a hospitalized cohort of AKI cases managed by an AKI-nephrology team, drug-induced AKI (DI-AKI) accounted for 19.3% of AKI, with a mechanistic taxonomy: ATN (77%), AIN (15.2%), and crystal-induced nephropathy (2.6%); vancomycin was a leading nephrotoxin and associated with higher AKST and death (https://doi.org/10.3389/fmed.2024.1459170; published Oct 29, 2024) (garcia2024druginducedacutekidney pages 1-2, garcia2024druginducedacutekidney pages 2-3, garcia2024druginducedacutekidney pages 3-5).
Mechanistic evidence from recent reviews supports disruption of the following process categories: - Regulated cell death (apoptotic process; necroptotic process; pyroptotic process; ferroptotic process) (li2024renaltubularepithelial pages 2-3, li2024renaltubularepithelial pages 13-14). - Inflammatory response / innate immune signaling (cytokine-mediated signaling, inflammasome activation; leukocyte adhesion and endothelial activation in sepsis-associated settings) (aguilar2024sepsisassociatedacutekidney pages 2-4, li2024renaltubularepithelial pages 13-14). - Response to oxidative stress and lipid peroxidation (central to ferroptosis; ROS-linked injury) (li2024renaltubularepithelial pages 2-3, li2024renaltubularepithelial pages 1-2). - Mitochondrial organization / quality control and metabolic process regulation (mitochondrial dysfunction and metabolic reprogramming are emphasized as AKI-to-AKD mechanisms) (kung2023acutekidneydisease pages 1-3, li2024renaltubularepithelial pages 16-16). - Cell cycle arrest / DNA damage response (a key maladaptive repair mechanism in AKD framing) (kung2023acutekidneydisease pages 1-3). - Extracellular matrix organization / fibrogenesis (pericyte-to-myofibroblast transition; epigenetic maintenance of profibrotic state) (kung2023acutekidneydisease pages 3-4).
Common inpatient triggers include infection/sepsis, hemodynamic instability, mechanical ventilation-related physiology, chloride/fluid perturbations, and nephrotoxic drug exposure (havaldar2024epidemiologicalstudyof pages 1-2, mekonnen2024hospitalacquiredacutekidney pages 6-8).
In sepsis-associated contexts, a key modern concept is that injury can occur despite preserved renal blood flow, via microcirculatory/endothelial dysfunction causing regional hypoxia plus inflammatory/oxidative injury (aguilar2024sepsisassociatedacutekidney pages 2-4).
Tubular cell injury engages regulated cell-death programs (ferroptosis, necroptosis, pyroptosis, apoptosis/PANoptosis), propagating necroinflammation and functional GFR decline (li2024renaltubularepithelial pages 2-3, li2024renaltubularepithelial pages 1-2).
If repair is incomplete, the 7–90-day period termed acute kidney disease (AKD) provides a mechanistic bridge to CKD, with drivers including cell-cycle arrest, epigenetic reprogramming, chronic inflammation, mitochondrial dysfunction, failed regeneration, and RAS activation (kung2023acutekidneydisease pages 1-3, kung2023acutekidneydisease pages 3-4).
In hospitalized cohorts, AKI that peaks later during admission (“in-hospital AKI”) is associated with worse outcomes than AKI present at admission. In one large cohort, in-hospital AKI had longer LOS (mean 26.6 vs 18.7 days) and higher in-hospital mortality (30.7% vs 13.8%) compared with admission AKI (esposito2024recognitionpatternsof pages 7-8).
In septic AKI, later-developing AKI is also linked to higher mortality than early/transient AKI; a 2024 review states: “the development of AKI later during an episode of sepsis has been associated with worse clinical outcomes and increased mortality rates (76.5% compared with 61.5% in early AKI)” (https://doi.org/10.7759/cureus.75992; Dec 2024) (aguilar2024sepsisassociatedacutekidney pages 10-11).
Mechanistically, HA-AKI manifests clinically as acute reductions in filtration and tubular function, often captured by: - Rising serum creatinine / azotemia (used for epidemiologic ascertainment in multiple studies) (esposito2024recognitionpatternsof pages 4-6, havaldar2024epidemiologicalstudyof pages 1-2). - Need for kidney replacement therapy (KRT/RRT) in severe cases; ICU HA-AKI cohort reported 15.9% required RRT during hospitalization (havaldar2024epidemiologicalstudyof pages 1-2). - In-hospital mortality and prolonged stay. ICU HA-AKI cohort mortality was 43.18% vs 14.41% without AKI (havaldar2024epidemiologicalstudyof pages 1-2).
Biomarkers are increasingly used to move from “late functional change” (creatinine/urine output) toward earlier “stress/injury” signals.
[TIMP-2]·[IGFBP7] + furosemide stress test (FST) to enrich for early RRT need in sepsis-AKI (prospective multicenter; published Jul 2024). In 100 sepsis patients with AKI stage ≥2, 32% required RRT within 7 days. A two-step workflow (FST screen → [TIMP-2]·[IGFBP7] at 2 h) improved prediction accuracy to 0.83 with specificity 0.96 and PPV 0.86 (https://doi.org/10.1186/s13613-024-01349-4) (palmowski2024predictiveenrichmentfor pages 1-2).
CCL14 vs [TIMP-2]·[IGFBP7] for predicting renal non-recovery in sepsis-AKI (prospective observational; published May 2024): For 7-day non-recovery prediction, CCL14 AUC 0.901 vs [TIMP-2]·[IGFBP7] AUC 0.730, with reported cutoffs and operating characteristics (https://doi.org/10.1186/s12882-024-03589-9) (nephrology2024predictiveperformanceof pages 7-8).
Electronic AKI alerting systems and linked order sets are widely implemented but show heterogeneous outcome effects.
Order set / care-bundle use with alerting (single-center cohort; published Feb 2024): An EHR-integrated AKI order set was used in 9.8% of AKI events and was associated with lower all-cause mortality (multivariable OR 0.72, 95% CI 0.57–0.91) and increased likelihood of AKI-stage improvement (multivariable OR 4.27, 95% CI 3.54–5.14), though LOS was longer when used (https://doi.org/10.1080/0886022X.2024.2313177) (chenxu2024impactofelectronic pages 1-2).
RCT-only evidence for alerts (meta-analysis; published Sep 2024): Across six RCTs (n=40,146), e-alerts showed no mortality benefit (RR 1.02), no reduction in creatinine or AKI progression, but increased dialysis (RR 1.14) and increased documentation (RR 1.21) (https://doi.org/10.1186/s12916-024-03639-x) (fu2024effectofelectronic pages 1-2).
Broader mixed-design synthesis (systematic review/meta-analysis; 2024): pooled estimates suggested modest AKI progression reduction (RR 0.91) but unclear mortality benefit and increased dialysis (RR 1.16) (chen2024electronicalertsystems pages 6-7).
Interpretation: The collective evidence supports the view that alerts improve recognition/documentation, but clinical outcome improvements require coupling alerts with actionable responses (order sets, care bundles, nephrology/pharmacy workflows) (chenxu2024impactofelectronic pages 1-2, fu2024effectofelectronic pages 1-2).
A key expert framing from a 2024 review is that sepsis-AKI is not simply “low renal blood flow,” but a syndrome in which endothelial activation and microcirculatory dysfunction can create patchy ischemia/hypoxia even when global renal flow is preserved (aguilar2024sepsisassociatedacutekidney pages 2-4).
A 2023 synthesis emphasizes AKD (7–90 days) as a clinically important period where persistent tubular injury, cell-cycle arrest, epigenetic changes, and metabolic dysfunction can drive progression to CKD, motivating structured follow-up and recurrence prevention (kung2023acutekidneydisease pages 1-3).
Hospital-acquired AKI results from convergent inpatient insults (sepsis/inflammation, microvascular dysfunction, nephrotoxins, ventilation/hemodynamic perturbations) that converge on renal tubular epithelial stress. TEC injury triggers regulated death programs (ferroptosis, necroptosis, pyroptosis, apoptosis/PANoptosis) and mitochondrial/metabolic dysfunction, amplifying inflammation and impairing epithelial repair. Microcirculatory endothelial activation and glycocalyx injury (especially in sepsis) create regional hypoxia and immune-thrombotic injury. Outcomes depend on whether repair is adaptive (successful redifferentiation and recovery) or maladaptive (cell-cycle arrest, persistent inflammation, epigenetic profibrotic programs and pericyte-to-myofibroblast transition), promoting AKD and long-term CKD risk (li2024renaltubularepithelial pages 2-3, aguilar2024sepsisassociatedacutekidney pages 2-4, kung2023acutekidneydisease pages 3-4, li2024renaltubularepithelial media 407547cb).
| Mechanistic Domain | Key Pathways/Processes | Key Genes/Proteins (HGNC) | Primary Cell Types (CL) | Anatomical Locations (UBERON) | Representative Chemicals (CHEBI) | Evidence |
|---|---|---|---|---|---|---|
| Regulated Cell Death: Ferroptosis | Lipid peroxidation; System Xc- inhibition; Iron metabolism dysregulation; Membrane rupture | GPX4, SLC7A11, ACSL4 | Kidney tubular epithelial cell (CL:0000653) | Proximal convoluted tubule (UBERON:0004134) | Iron (CHEBI:18248), Glutathione (CHEBI:16856), Lipid peroxides | Li et al. 2024 (li2024renaltubularepithelial pages 2-3, li2024renaltubularepithelial pages 1-2, li2024renaltubularepithelial pages 11-12) |
| Regulated Cell Death: Necroptosis | RIPK1-RIPK3 signaling; MLKL phosphorylation/oligomerization; "Necroinflammation" | RIPK1, RIPK3, MLKL | Kidney tubular epithelial cell (CL:0000653) | Renal tubule (UBERON:0001231) | TNF-alpha (CHEBI:132922) | Li et al. 2024 (li2024renaltubularepithelial pages 2-3, li2024renaltubularepithelial pages 13-14) |
| Inflammation & Pyroptosis | NLRP3 inflammasome activation; STING-mtROS axis; Gasdermin pore formation; Cytokine release | NLRP3, GSDMD, CASP1, TMEM173 (STING) | Kidney tubular epithelial cell; Macrophage (CL:0000235) | Renal interstitium (UBERON:0001233) | IL-1beta, IL-18, Lipopolysaccharide (CHEBI:16412) | Li et al. 2024 (li2024renaltubularepithelial pages 13-14, li2024renaltubularepithelial pages 16-16) |
| Mitochondrial & Metabolic Reprogramming | Defective Fatty Acid Oxidation (FAO); Shift to Glycolysis; Mitochondrial fission/fusion; Mitophagy failure | CPT1A, PPARA, PKM, PINK1, PRKN | Proximal straight tubule epithelial cell (CL:0002306) | Mitochondrion (GO:0005739) in Kidney (UBERON:0002113) | Fatty acids (CHEBI:35366), Lactate (CHEBI:24996), ATP (CHEBI:15422) | Cao et al. 2025 (cao2025mitochondrialdysfunctionand pages 4-6); Li et al. 2024 (li2024renaltubularepithelial pages 16-16) |
| Microvascular & Endothelial Dysfunction | Glycocalyx degradation; Endothelial activation; Leukocyte adhesion; Microthrombosis; Capillary shunting | VCAM1, ICAM1, SELE (Selectins) | Endothelial cell (CL:0000115) | Glomerular capillary (UBERON:0004642); Peritubular capillary | Nitric oxide (CHEBI:16480), VEGF | Aguilar et al. 2024 (aguilar2024sepsisassociatedacutekidney pages 2-4, aguilar2024sepsisassociatedacutekidney pages 10-11) |
| Nephrotoxicity (Drug-Induced) | Acute Tubular Necrosis (ATN); Acute Interstitial Nephritis (AIN); Intratubular crystal deposition; Oxidative stress | SLC22A6 (OAT1 - implied), LRP2 (Megalin - implied) | Kidney tubular epithelial cell | Renal tubule; Renal interstitium | Vancomycin (CHEBI:9948), Cisplatin (CHEBI:27899), Contrast media | Garcia et al. 2024 (garcia2024druginducedacutekidney pages 1-2, garcia2024druginducedacutekidney pages 2-3, garcia2024druginducedacutekidney pages 6-8) |
| Maladaptive Repair & Fibrosis | G2/M cell cycle arrest; Pericyte-to-myofibroblast transition; Epigenetic hypermethylation | TGFB1, RASAL1, ACTA2 (alpha-SMA) | Kidney pericyte (CL:0000669); Myofibroblast | Renal interstitium | 5-azacytidine (CHEBI:2704 - experimental reversal) | Kung et al. 2023 (kung2023acutekidneydisease pages 3-4) |
Table: This table summarizes the core pathophysiological domains of HA-AKI, detailing key pathways, molecular players, affected cell types, and anatomical sites, along with associated chemical entities and supporting evidence from recent literature.
A schematic figure summarizing adaptive vs maladaptive TEC repair trajectories (Figure 1, Li et al. 2024) is available (li2024renaltubularepithelial media 407547cb).
References
(havaldar2024epidemiologicalstudyof pages 1-2): Amarja Ashok Havaldar, E.A. Chinny Sushmitha, Sahad Bin Shrouf, Monisha H. S., Madhammal N., and Sumithra Selvam. Epidemiological study of hospital acquired acute kidney injury in critically ill and its effect on the survival. Scientific Reports, Nov 2024. URL: https://doi.org/10.1038/s41598-024-79533-6, doi:10.1038/s41598-024-79533-6. This article has 12 citations and is from a peer-reviewed journal.
(esposito2024recognitionpatternsof pages 7-8): Pasquale Esposito, Francesca Cappadona, Marita Marengo, Marco Fiorentino, Paolo Fabbrini, Alessandro Domenico Quercia, Francesco Garzotto, Giuseppe Castellano, Vincenzo Cantaluppi, and Francesca Viazzi. Recognition patterns of acute kidney injury in hospitalized patients. Clinical Kidney Journal, Jul 2024. URL: https://doi.org/10.1093/ckj/sfae231, doi:10.1093/ckj/sfae231. This article has 15 citations and is from a peer-reviewed journal.
(esposito2024recognitionpatternsof pages 1-2): Pasquale Esposito, Francesca Cappadona, Marita Marengo, Marco Fiorentino, Paolo Fabbrini, Alessandro Domenico Quercia, Francesco Garzotto, Giuseppe Castellano, Vincenzo Cantaluppi, and Francesca Viazzi. Recognition patterns of acute kidney injury in hospitalized patients. Clinical Kidney Journal, Jul 2024. URL: https://doi.org/10.1093/ckj/sfae231, doi:10.1093/ckj/sfae231. This article has 15 citations and is from a peer-reviewed journal.
(esposito2024recognitionpatternsof pages 4-6): Pasquale Esposito, Francesca Cappadona, Marita Marengo, Marco Fiorentino, Paolo Fabbrini, Alessandro Domenico Quercia, Francesco Garzotto, Giuseppe Castellano, Vincenzo Cantaluppi, and Francesca Viazzi. Recognition patterns of acute kidney injury in hospitalized patients. Clinical Kidney Journal, Jul 2024. URL: https://doi.org/10.1093/ckj/sfae231, doi:10.1093/ckj/sfae231. This article has 15 citations and is from a peer-reviewed journal.
(li2024renaltubularepithelial pages 1-2): Zuo-Lin Li, Xin-Yan Li, Yan Zhou, Bin Wang, Lin-Li Lv, and Bi-Cheng Liu. Renal tubular epithelial cells response to injury in acute kidney injury. eBioMedicine, 107:105294, Sep 2024. URL: https://doi.org/10.1016/j.ebiom.2024.105294, doi:10.1016/j.ebiom.2024.105294. This article has 93 citations and is from a peer-reviewed journal.
(li2024renaltubularepithelial media 407547cb): Zuo-Lin Li, Xin-Yan Li, Yan Zhou, Bin Wang, Lin-Li Lv, and Bi-Cheng Liu. Renal tubular epithelial cells response to injury in acute kidney injury. eBioMedicine, 107:105294, Sep 2024. URL: https://doi.org/10.1016/j.ebiom.2024.105294, doi:10.1016/j.ebiom.2024.105294. This article has 93 citations and is from a peer-reviewed journal.
(li2024renaltubularepithelial pages 2-3): Zuo-Lin Li, Xin-Yan Li, Yan Zhou, Bin Wang, Lin-Li Lv, and Bi-Cheng Liu. Renal tubular epithelial cells response to injury in acute kidney injury. eBioMedicine, 107:105294, Sep 2024. URL: https://doi.org/10.1016/j.ebiom.2024.105294, doi:10.1016/j.ebiom.2024.105294. This article has 93 citations and is from a peer-reviewed journal.
(li2024renaltubularepithelial pages 11-12): Zuo-Lin Li, Xin-Yan Li, Yan Zhou, Bin Wang, Lin-Li Lv, and Bi-Cheng Liu. Renal tubular epithelial cells response to injury in acute kidney injury. eBioMedicine, 107:105294, Sep 2024. URL: https://doi.org/10.1016/j.ebiom.2024.105294, doi:10.1016/j.ebiom.2024.105294. This article has 93 citations and is from a peer-reviewed journal.
(aguilar2024sepsisassociatedacutekidney pages 2-4): Martin Gerardo Aguilar, Hassen A AlHussen, Prenika Devadas Gandhi, Priyadeep Kaur, Mounica A Pothacamuri, Mariam Altaf Husain Talikoti, Nandita Avula, Pallavi Shekhawat, Alisson Barbosa Silva, Arshpreet Kaur, and Manju Rai. Sepsis-associated acute kidney injury: pathophysiology and treatment modalities. Cureus, Dec 2024. URL: https://doi.org/10.7759/cureus.75992, doi:10.7759/cureus.75992. This article has 21 citations.
(kung2023acutekidneydisease pages 1-3): Chin-Wei Kung and Yu-Hsiang Chou. Acute kidney disease: an overview of the epidemiology, pathophysiology, and management. Kidney Research and Clinical Practice, 42:686-699, Nov 2023. URL: https://doi.org/10.23876/j.krcp.23.001, doi:10.23876/j.krcp.23.001. This article has 51 citations.
(li2024renaltubularepithelial pages 16-16): Zuo-Lin Li, Xin-Yan Li, Yan Zhou, Bin Wang, Lin-Li Lv, and Bi-Cheng Liu. Renal tubular epithelial cells response to injury in acute kidney injury. eBioMedicine, 107:105294, Sep 2024. URL: https://doi.org/10.1016/j.ebiom.2024.105294, doi:10.1016/j.ebiom.2024.105294. This article has 93 citations and is from a peer-reviewed journal.
(li2024renaltubularepithelial pages 13-14): Zuo-Lin Li, Xin-Yan Li, Yan Zhou, Bin Wang, Lin-Li Lv, and Bi-Cheng Liu. Renal tubular epithelial cells response to injury in acute kidney injury. eBioMedicine, 107:105294, Sep 2024. URL: https://doi.org/10.1016/j.ebiom.2024.105294, doi:10.1016/j.ebiom.2024.105294. This article has 93 citations and is from a peer-reviewed journal.
(kung2023acutekidneydisease pages 3-4): Chin-Wei Kung and Yu-Hsiang Chou. Acute kidney disease: an overview of the epidemiology, pathophysiology, and management. Kidney Research and Clinical Practice, 42:686-699, Nov 2023. URL: https://doi.org/10.23876/j.krcp.23.001, doi:10.23876/j.krcp.23.001. This article has 51 citations.
(mekonnen2024hospitalacquiredacutekidney pages 6-8): Nahom Mekonnen, Tigist Leulseged, Buure Hassen, Kidus Yemaneberhan, Helen Berhe, Nebiat Mera, Anteneh Beyene, Lidiya Zenebe Getachew, Birukti Habtezgi, and Feven Abriha. Hospital-acquired acute kidney injury in non-critical medical patients in a developing country tertiary hospital: incidence and predictors. International Journal of Nephrology and Renovascular Disease, Volume 17:125-133, Apr 2024. URL: https://doi.org/10.2147/ijnrd.s454987, doi:10.2147/ijnrd.s454987. This article has 3 citations.
(mekonnen2024hospitalacquiredacutekidney pages 1-2): Nahom Mekonnen, Tigist Leulseged, Buure Hassen, Kidus Yemaneberhan, Helen Berhe, Nebiat Mera, Anteneh Beyene, Lidiya Zenebe Getachew, Birukti Habtezgi, and Feven Abriha. Hospital-acquired acute kidney injury in non-critical medical patients in a developing country tertiary hospital: incidence and predictors. International Journal of Nephrology and Renovascular Disease, Volume 17:125-133, Apr 2024. URL: https://doi.org/10.2147/ijnrd.s454987, doi:10.2147/ijnrd.s454987. This article has 3 citations.
(garcia2024druginducedacutekidney pages 1-2): Georgia Garcia, Vinicius Repetti Pacchini, Welder Zamoner, Andre Luis Balbi, and Daniela Ponce. Drug-induced acute kidney injury: a cohort study on incidence, identification of pathophysiological mechanisms, and prognostic factors. Frontiers in Medicine, Oct 2024. URL: https://doi.org/10.3389/fmed.2024.1459170, doi:10.3389/fmed.2024.1459170. This article has 12 citations.
(garcia2024druginducedacutekidney pages 2-3): Georgia Garcia, Vinicius Repetti Pacchini, Welder Zamoner, Andre Luis Balbi, and Daniela Ponce. Drug-induced acute kidney injury: a cohort study on incidence, identification of pathophysiological mechanisms, and prognostic factors. Frontiers in Medicine, Oct 2024. URL: https://doi.org/10.3389/fmed.2024.1459170, doi:10.3389/fmed.2024.1459170. This article has 12 citations.
(garcia2024druginducedacutekidney pages 3-5): Georgia Garcia, Vinicius Repetti Pacchini, Welder Zamoner, Andre Luis Balbi, and Daniela Ponce. Drug-induced acute kidney injury: a cohort study on incidence, identification of pathophysiological mechanisms, and prognostic factors. Frontiers in Medicine, Oct 2024. URL: https://doi.org/10.3389/fmed.2024.1459170, doi:10.3389/fmed.2024.1459170. This article has 12 citations.
(aguilar2024sepsisassociatedacutekidney pages 10-11): Martin Gerardo Aguilar, Hassen A AlHussen, Prenika Devadas Gandhi, Priyadeep Kaur, Mounica A Pothacamuri, Mariam Altaf Husain Talikoti, Nandita Avula, Pallavi Shekhawat, Alisson Barbosa Silva, Arshpreet Kaur, and Manju Rai. Sepsis-associated acute kidney injury: pathophysiology and treatment modalities. Cureus, Dec 2024. URL: https://doi.org/10.7759/cureus.75992, doi:10.7759/cureus.75992. This article has 21 citations.
(palmowski2024predictiveenrichmentfor pages 1-2): Lars Palmowski, Simone Lindau, Laura Contreras Henk, Britta Marko, Andrea Witowski, Hartmuth Nowak, Sandra E. Stoll, Kai Zacharowski, Bernd W. Böttiger, Jürgen Peters, Michael Adamzik, Fabian Dusse, and Tim Rahmel. Predictive enrichment for the need of renal replacement in sepsis-associated acute kidney injury: combination of furosemide stress test and urinary biomarkers timp-2 and igfbp-7. Annals of Intensive Care, Jul 2024. URL: https://doi.org/10.1186/s13613-024-01349-4, doi:10.1186/s13613-024-01349-4. This article has 12 citations and is from a peer-reviewed journal.
(nephrology2024predictiveperformanceof pages 7-8): Bmc Nephrology, Wenxiong Li, Licheng, Huimiao Jia, and Yijia Jiang. Predictive performance of two types of urinary biomarkers for renal non-recovery in sepsis-associated acute kidney injury: a prospective observational study. BMC Nephrology, May 2024. URL: https://doi.org/10.1186/s12882-024-03589-9, doi:10.1186/s12882-024-03589-9. This article has 3 citations and is from a peer-reviewed journal.
(chenxu2024impactofelectronic pages 1-2): Michael Chen-Xu, Christopher Kassam, Emma Cameron, Szymon Ryba, and Vivian Yiu. Impact of electronic aki alert/care bundle on aki inpatient outcomes: a retrospective single-center cohort study. Renal Failure, Feb 2024. URL: https://doi.org/10.1080/0886022x.2024.2313177, doi:10.1080/0886022x.2024.2313177. This article has 4 citations and is from a peer-reviewed journal.
(fu2024effectofelectronic pages 1-2): Zhangning Fu, Xiuzhen Hao, Yangfan Lv, Quan Hong, Zhe Feng, and Chao Liu. Effect of electronic alerts on the care and outcomes in patients with acute kidney injury: a meta-analysis and trial sequential analysis. BMC Medicine, Sep 2024. URL: https://doi.org/10.1186/s12916-024-03639-x, doi:10.1186/s12916-024-03639-x. This article has 6 citations and is from a domain leading peer-reviewed journal.
(chen2024electronicalertsystems pages 6-7): JJ Chen, TH Lee, MJ Chan, TY Tsai, and PC Fan. Electronic alert systems for patients with acute kidney injury: a systematic review and meta-analysis. Unknown journal, 2024.
(cao2025mitochondrialdysfunctionand pages 4-6): Meiling Cao, Xueqi Zhao, Fang Xia, Mingyu Shi, Danyang Zhao, Lei Li, and Hongkun Jiang. Mitochondrial dysfunction and metabolic reprogramming in acute kidney injury: mechanisms, therapeutic advances, and clinical challenges. Frontiers in Physiology, Aug 2025. URL: https://doi.org/10.3389/fphys.2025.1623500, doi:10.3389/fphys.2025.1623500. This article has 8 citations.
(garcia2024druginducedacutekidney pages 6-8): Georgia Garcia, Vinicius Repetti Pacchini, Welder Zamoner, Andre Luis Balbi, and Daniela Ponce. Drug-induced acute kidney injury: a cohort study on incidence, identification of pathophysiological mechanisms, and prognostic factors. Frontiers in Medicine, Oct 2024. URL: https://doi.org/10.3389/fmed.2024.1459170, doi:10.3389/fmed.2024.1459170. This article has 12 citations.